Characterizing markets for biopharmaceutical innovations
Subtitle: do biologics differ from small molecules?
By: Mark Trusheim, Murray L. Aitken, Ernst R. Berndt
Contributors: Aitken, Murray L.; Berndt, Ernst R.; National Bureau of Economic Research
Series: NBER working paper series -- working paper 16014; Working paper series (National Bureau of Economic Research : Online) -- working paper no. 16014.
Publisher: National Bureau of Economic Research
Published: 2010
Place of publication: Cambridge, MA
Language: eng
Format: Electronic resource
Description: "The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.  Much has been written about the seemingly less formal, more agile biotechnology industry and its extensive interactions with academia and startups, as well as its distinct scientific, manufacturing and regulatory profile.  Employing a data base encompassing all 96 biologics and 212 small molecules newly launched in the U.S.  between 1998Q1 and 2008Q4, we compare their downstream clinical and commercial characteristics -- therapeutic class concentration, launch delays following approval, Orphan Drug and priority review status, supplemental indications, black box warning and safety record, and pricing and revenue growth during the product life cycle.  We conclude that the market dynamics of biologics differ substantially from those of small molecules, although therapeutic class composition plays a major role"--National Bureau of Economic Research web site.
Notes: Title from PDF file as viewed on 5/27/2010.

Includes bibliographical references.

Also available in print.

System requirements: Adobe Acrobat Reader.

Mode of access: World Wide Web.